Observational studyBMC infectious diseases2025
Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kidney dysfunction in adults living with HIV and HBV: a 10-year retrospective cohort study across seven Asia-Pacific countries.AIDS research and therapy · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndonesia started transitioning people living with HIV (PLHIV) from Nevirapine (NVP)-based antiretroviral therapy to tenofovir (TDF)-lamivudine-dolutegravir fixed-dose combination (TLD) in 2023. We aimed to evaluate changes in estimated glomerular filtration rate (eGFR) and predictors of rapid eGFR decline within 6 months during this programmatic dolutegravir (DTG) transition.
methodsThis prospective observational study included all adult PLHIV (≥ 18 years old) who received an NVP-based regimen initially, had baseline eGFR of more than 60 mL/min/1.73m2 before the transition, and underwent the DTG transition program in Cipto Mangunkusumo Hospital from March 2023 to January 2024. Participants who did not have at least two eGFR measurements were not included in the study. The decline in the eGFR during the study period was defined by a minimum 25% eGFR decline from baseline, and multivariate regression was used for analysis.
resultsA total of 329 participants were transitioned to TLD. Of these patients, 242 (73.6%) transitioned from the zidovudine-lamivudine fixed-dose combination and NVP (AZT/3TC+NVP), and 87 (26.4%) transitioned from TDF+3TC+NVP. Within six months of observation, 87.2% of participants had eGFR decline. Sixty-one participants (18.5%) experienced rapid eGFR decline: 19.8% and 14.9% in those who had previously used AZT and TDF, respectively. Factors related to rapid eGFR decline were hypertension (aRR 1.87; 95% CI: 1.15 – 3.05) and longer usage of previous ART (aRR 1.05; 95% CI: 1.01 – 1.10).
conclusionRapid eGFR decline after transitioning from an NVP-based regimen to TLD warrants close monitoring, especially in patients with hypertension and longer use of ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.